Geneos Wealth Management Inc. Acquires 1,626 Shares of Stryker Corporation $SYK

Geneos Wealth Management Inc. increased its holdings in Stryker Corporation (NYSE:SYK) by 7.3% during the first quarter, Holdings Channel reports. The firm owned 23,958 shares of the medical technology company’s stock after acquiring an additional 1,626 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $7,872,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SYK. Czech National Bank increased its holdings in shares of Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Daymark Wealth Partners LLC lifted its position in shares of Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after buying an additional 37,307 shares in the last quarter. Varma Mutual Pension Insurance Co boosted its stake in Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. Wealthcare Advisory Partners LLC boosted its stake in Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after buying an additional 6,774 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Stryker during the 3rd quarter valued at approximately $17,547,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of Stryker stock opened at $330.64 on Friday. The stock has a market cap of $126.76 billion, a price-to-earnings ratio of 38.27, a price-to-earnings-growth ratio of 2.03 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a 50 day moving average price of $312.00 and a 200-day moving average price of $336.94. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Citigroup cut their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.